-+ 0.00%
-+ 0.00%
-+ 0.00%

Erasca Secures FDA Clearance For First-In-Class Pan-KRAS Inhibitor ERAS-4001

Benzinga·06/02/2025 12:29:57
Listen to the news

Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance

Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant (KRASm) solid tumors.